Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes

Value in Health

Volumn 14, Issue 1, 2011, Pages 24-33

  Schwenkglenks, Matthias ^a   Brazier, John E ^b   Szucs, Thomas D ^a,c   Fox, Keith A A ^d  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Acute coronary syndrome; Anticoagulants; Bivalirudin; Cost utility analysis; United Kingdom

Indexed keywords

ABCIXIMAB; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; THIENOPYRIDINE DERIVATIVE; TIROFIBAN; ANTICOAGULANT AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; HIRUDIN DERIVATIVE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT; PYRIDINE DERIVATIVE; RECOMBINANT PROTEIN; TYROSINE;

ACUTE CORONARY SYNDROME; ADULT; ANALYSIS; ARTICLE; BLEEDING; CLINICAL PRACTICE; CLINICAL STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HOSPITALIZATION COST; HUMAN; INVASIVE PROCEDURE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; SURVIVAL TIME; SURVIVOR; UNITED KINGDOM; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION TREE; DRUG ANTAGONISM; DRUG COMBINATION; ECONOMICS; HEALTH CARE COST; HEART MUSCLE REVASCULARIZATION; MIDDLE AGED; STATISTICAL MODEL; SURVIVAL;

ACUTE CORONARY SYNDROME; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; COST-BENEFIT ANALYSIS; DECISION TREES; DRUG THERAPY, COMBINATION; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HEPARIN; HIRUDINS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; MYOCARDIAL REVASCULARIZATION; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRIDINES; QUALITY-ADJUSTED LIFE YEARS; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TYROSINE;

EID: 79952664527     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.10.025     Document Type: Article

References (35)

1. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-16. (Pubitemid 44791162)
2. Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 2007;298:2497-506. (Pubitemid 350223536)
3. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703. (Pubitemid 39062523)
4. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30. (Pubitemid 351724451)
5. Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009;374:1149-59.
6. European Medicines Agency. Angiox European Public Assessment Report. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/angiox/angiox. htm. [Accessed May 14, 2008.]
7. The GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001;141:190-9.
8. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. Available from: http://www.nice.org.uk/ aboutnice/howwework/devnicetech/technologyappraisalprocessguides/ guidetothemethodsoftechnologyappraisal.jsp?domedia=1&mid= B52851A3-19B9-E0B5-D48284D172BD8459. [Accessed June 15, 2010.]
9. Stone GW, Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J 2004;148:764-75.
10. Center for Outcomes Research-University of Massachusetts Medical School. Standard definitions adopted in GRACE. Available from: http://www.outcomes- umassmed.org/GRACE/index.cfm. [Accessed June 30, 2009.]
11. Palmer S, Sculpher M, Philips Z, et al. A cost-effectiveness model comparing alternative management strategies for the use of glycoprotein IIB/IIIA antagonists in non-ST-elevation acute myocardial infarction. NICE Appraisal Report. Available from: http://www.nice.org.uk/Docref.asp?d=32030. [Accessed June 30, 2009.]
12. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 1982;73:883-8. (Pubitemid 13211834)
13. Office for National Statistics. Interim Life Tables, United Kingdom, 1980-82 to 2005-07. Available from: http://www.statistics.gov. uk/StatBase/Product.asp?vlnk=14459. [Accessed June 30, 2009.]
14. Lacey EA, Walters SJ. Continuing inequality: gender and social class influences on self perceived health after a heart attack. J Epidemiol Community Health 2003;57:622-7. (Pubitemid 36930291)
15. Hill RA, Boland A, Dickson R, et al. Drug-eluting stents: a systematic review and economic evaluation. Health Technol Assess 2007;11: iii, xi-221.
16. Personal Social Services Research Unit. Unit Costs of Health and Social Care 2008. Available from: http://www.pssru.ac.uk/pdf/uc/uc2008/uc2008- inflationindices.pdf. [Accessed June 30, 2009.]
17. British National Formulary. BNF 57. London: BMJ Publishing Group Ltd and RPS Publishing, 2008.
18. Department of Health. NHS reference costs 2007-08. Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-098945. [Accessed June 30, 2009.]
19. Department of Health. NHS reference costs 2005-06. Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-062884. [Accessed June 30, 2009.]
20. Denvir MA, Lee AJ, Rysdale J, et al. Comparing performance between coronary intervention centres requires detailed case-mix adjusted analysis. J Public Health (Oxf) 2004;26:177-84. (Pubitemid 39030855)
21. Information and Statistics Scotland. Scottish Financial Returns (SFRs) 2007. Available from: http://www.isdscotland.org/isd/5800.html. [Accessed June 30, 2009.]
22. Hlatky MA, Boothroyd DB, Brooks MM, et al. Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty. Am Heart J 1999;138:376-83. (Pubitemid 29379694)
23. Rao SV, Kaul PR, Liao L, et al. Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 2008;155:369-74.
24. Cohen DJ, Lincoff AM, Lavelle TA, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 2004;44:1792-800. (Pubitemid 39424077)
25. Lincoff AM, Mark DB, Tcheng JE, et al. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 2000;102:2923-9.
26. Pinto DS, Stone GW, Shi C, et al. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. J Am Coll Cardiol 2008;52:1758-68.
27. Department of Health. NHS reference costs 2003 and National tariff 2004: payment by results core tools 2004. Available from: http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-4070195. [Accessed June 30, 2009.]
28. Bravo Vergel Y, Palmer S, Asseburg C, et al. The Cost-Effectiveness of Primary Angioplasty Compared to Thrombolytic Therapy for Acute Myocardial Infarction in the UK NHS. York: University of York, 2006.
29. Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009;360:2176-90.
30. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 2007;297:591-602.
31. Borg S, Persson U, Allikmets K, et al. Comparative costeffectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model. Clin Ther 2006;28:1947-59. (Pubitemid 46043509)
32. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes (3rd ed.). Oxford: Oxford University Press, 2005.
33. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007;49:1362-8. (Pubitemid 46476844)
34. Rassen JA, Mittleman MA, Glynn RJ, et al. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J 2010;31:561-72.
35. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003;163:2345-53. (Pubitemid 37310196)